Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 8
Submit an article Journal homepage
40
Views
16
CrossRef citations to date
0
Altmetric
Research Article

Phase II Study of Sequential Topotecan and Etoposide in Patients with Intermediate Grade Non-Hodgkin's Lymphoma: A National Cancer Institute of Canada Clinical Trials Group Study

Michael Crump Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Room 5-108, Toronto M5G 2M9, Canada
,
Stephen Couban Department of Hematology, Queen Elizabeth II, Health Sciences Centre, Halifax, Canada
,
Ralph Meyer Hamilton Health Science Corporation-Henderson Site, Hamilton, Canada
,
Leona Rudinskas Department of Medical Oncology, Humber River Regional Hospital--Church Site, Toronto, Canada
,
Brent Zanke Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Room 5-108, Toronto M5G 2M9, Canada
,
Stefan Gluck Department of Medicine, Tom Baker Cancer Centre, Calgary, Canada
,
Andrew Maksymiuk Section of Medical Oncology, Saskatoon Cancer Centre, Saskatoon, Canada
,
Paul Hoskins Department of Medical Oncology, BC Cancer Agency--Vancouver CC, Vancouver, Canada
,
Sarah Matthews National Cancer Institute of Canada--Clinical Trials Group, Kingston, Canada
&
Elizabeth Eisenhauer National Cancer Institute of Canada--Clinical Trials Group, Kingston, Canada
 show all
Pages 1581-1587 | Published online: 01 Jul 2009

  • Fisher, R.I., Gaynor, E.R., Dahlberg, S., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, Jr, C.A. and Miller, T.P. (1993) "Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma", New England Journal of Medicine 328, 1002 - 1006
  • Gordon, L.I., Harrington, D., Andersen, J., Colgan, J., Neiman, R., Mann, R., Resnick, G.D., Barcos, M., Gottlieb, A. and O'Connell, M. (1992) "Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma", New England Journal of Medicine 327, 1342 - 1349
  • Sertoli, M.R., Santini, G., Chisesi, T., Congiu, A.M., Rubagotti, A., Contu, A., Salvagno, L., Coser, P., Porcellini, A., Vespignani, M., Capnist, G., Rossi, E., Mangoni, L., Fabris, P., Vinante, O., Tedeschi, L., Endrizzi, L., Miglio, L.P., Perrotta, A., Rosso, R., Damasio, E. and Rizzoli, V. (1994) "MACOP-B versus Pro-MACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group", Journal of Clinical Oncology 12, 1366 - 1374
  • Wolf, M., Matthews, J.P., Stone, J., Grigg, A. and Benson, W. (1999) "Confirmation of a long-term survival advantage of MACOP-B over CHOP in intermediate grade non-Hodgkin's lymphoma (NHL)", Annals of Oncology 10 (Suppl. 3), 59, Abstract #201
  • Rodriguez-Monge, E.J. and Cabanillas, F. (1997) "Long-term follow-up of platinum based lymphoma salvage regimens: the M.D. Anderson Cancer Center experience", Hematology/Oncology Clinics of North America 11, 937 - 947
  • Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J-Y., Harousseau, J.-L., Coiffier, B., Biron, P., Mandelli, F. and Chauvin, F. (1995) "Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma", New England Journal of Medicine 333, 1540 - 1545
  • Haioun, C., Lepage, E., Gisselbrecht, C., Coiffier, B., Bosly, A., Tilly, H., Morel, P., Nouvel, C., Herbrecht, R., D'Agay, M.F., Faulard, P. and Reyes, F. (1994) "Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients", Journal of Clinical Oncology 12, 2543 - 2551
  • Verdonck, L.F., Van Putten, W.L.J., Hagenbeek, A., Schouten, H.C., Sonneveld, P., van Imhoff, G.W., Kluin-Nelemans, H.C., Raemaekers, J.M., van Oers, R.H., Haak, H.L., Schots, R., Kekker, A.W., de Gast, G.C. and Lowenberg, B. (1995) "Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma", New England Journal of Medicine 332, 1045 - 1051
  • Kluin-Nelemans, H.C., Zagonel, V., Anastasopoulou, A., Bron, D., Roozendaal, K.J., Noordijk, E.M., Musson, H., Teodorovic, I., Maes, B., Carbone, A., Carde, P. and Thomas, J. (2001) "Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study", Journal of the National Cancer Institute 93 (1), 22 - 30
  • Pommier, Y. (1993) "DNA topoisomerase I and II in cancer chemotherapy: update and perspectives", Cancer Chemotherapy and Pharmacology 32, 103 - 108
  • ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davidson, N., Spanczynski, M., Bolis, G., Malmstrom, H., Coleman, R., Fields, S.C. and Heron, J.F. (1997) "Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer", Journal of Clinical Oncology 15, 2183 - 2193
  • von Pawel, J., Schiller, J.A., Shepherd, F.A., Fields, S.Z., Kleisbauer, J.P., Chrysson, N.G., Stewart, D.J., Clark, P.I., Palmer, M.C., Depierre, A., Carmichael, J., Krebs, J.B., Ross, G., Lane, S.R. and Gralla, R. (1999) "Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer", Journal of Clinical Oncology 17, 658 - 667
  • Ohno, R., Okada, K., Masaoka, T., Kuramoto, A., Arima, T., Yoshida, Y., Ariyoshi, H., Ichimaru, M., Sakai, Y., Oguro, M., Ito, Y., Morishima, Y., Yokomaku, S. and Ota, K. (1990) "An early Phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma", Journal of Clinical Oncology 8, 1907 - 1912
  • Kaufmann, S.H. (1991) "Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line", Cancer Research 51, 1129 - 1136
  • Whitacre, C.M., Zborowska, A., Gordon, N.H., Mackay, W. and Berger, N.A. (1997) "Topotecan increases topoisomerase IIα levels and sensitivity to treatment with etoposide in schedule-dependent process", Cancer Research 57, 1425 - 1428
  • Slevin, M.L., Clark, P.I., Joel, S.P., Malik, S., Osborne, R.J., Gregory, W.M., Lowe, D.G., Reznek, R.H. and Wrigley, P.L. (1989) "A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer", Journal of Clinical Oncology 7, 1333 - 1340
  • Splinter, T.A., van der Gaast, A. and Kok, T.C. (1992) "What is the optimum dose and duration of treatment with etoposide? I. Maximum tolerated duration of daily treatment with 50, 75 and 100 mg of oral etoposide", Seminars in Oncology 19 (6 Suppl 14), 1 - 7
  • Hainsworth, J.D., Johnson, D.H., Frazier, S.R. and Greco, F.A. (1990) "Chronic daily administration of oral etoposide in refractory lymphoma", European Journal of Cancer 26, 818 - 821
  • Goss, P., Burkes, R., Rudinskas, L., King, M., Chow, W., Myers, R., Davidson, M., Poldre, P., Crump, M., Sutton, D. and Scott, G. (1995) "A phase II trial of prednisone, oral etoposide and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients", Leukemia and Lymphoma 18, 145 - 152
  • Herben, V.M.M., ten Bokkel Huinink, W.W., Dubbleman, A.C., Mandjes, I.A.M., Groot, Y., van Gortel-van Zomeren, D.M. and Beijnen, J.H. (1997) "Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide", British Journal of Cancer 76, 1500 - 1508
  • Girouard, C., Dufresne, J., Imrie, K., Stewart, A.K., Brandwein, J., Prince, H.M., Pantolony, D., Keating, A. and Crump, M. (1997) "Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation", Annals of Oncology 8, 675 - 680
  • National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage (1982). "The non-Hodgkin's lymphoma pathologic classification project". Cancer, 49 pp. 2112-2135.
  • Meyer, R.M., Quirt, I.C., Skillings, J.R., Cripps, M.C., Bramwell, V.H., Weinerman, B.H., Gospodarowicz, M.K., Burns, B.F., Sargeant, A.M., Shepherd, L.E., Zee, B. and Hryniuk, W.M. (1993) "Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma", New England Journal of Medicine 329, 1770 - 1776
  • "A predictive model for aggressive non-Hodgkin's lymphoma". The international non-Hodgkin's lymphoma prognostic factors project. New England Journal of Medicine 329 (1993) pp. 987-994.
  • Kim, R., Hirabayashi, N., Nishiyama, M., Jinushi, K., Toge, T. and Okada, K. (1992) "Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice", International Journal of Cancer 50, 760 - 766
  • Sugimoto, Y., Tsukahara, S., Oh-hara, T., Liu, L.F. and Tsuruo, T. (1990) "Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines", Cancer Research 50, 7962 - 7965
  • Ando, M., Eguchi, K., Shinkai, T., Tamura, T., Ohe, Y., Yamamoto, N., Kurata, T., Kasai, T., Ohmatsu, H., Kubota, K., Sekine, I., Hojo, N., Matsumoto, T., Kodama, T., Kakinuma, R., Nishiwaki, Y. and Saijo, N. (1997) "Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small cell lung cancer", British Journal of Cancer 76 (11), 1494 - 1499
  • Hammond, L.A., Eckardt, J.R., Ganapathi, R., Burris, H.A., Rodriguez, G.A., Eckhardt, S.G., Rothenberg, M.L., Weiss, G.R., Kuhn, J.G., Hodges, S., Von Hoff, D.D. and Rowinsky, E.K. (1998) "A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide", Clinical Cancer Research 4, 1459 - 1467
  • Kraut, E.H., Balcerzak, S.P. and Young, D. (1998) "A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio state phase 2 consortium study", Proceedings of the American Society of Clinical Oncology 17, 29a, Abstract #111
  • Cabanillas, F. (1999) "The role of topoisomerase I inhibitors in the treatment of non-Hodgkin's lymphoma", Seminars in Hematology 36 (Suppl. 8), 11 - 15
  • Wilson, W.H., Little, R., Pearson, D., Jaffe, E.S., Steinberg, S.M., Cheson, B.D., Humphrey, R., Kohler, D.R. and Elwood, P. (1998) "Phase II and dose-escalation with or without granulocyte colony-stimulation factor study of 9-aminocaptothecin in relapsed and refractory lymphomas", Journal of Clinical Oncology 16, 2345 - 2357
  • Tolcher, A.W., O'Shaughnessy, J.A., Weiss, R.B., Zujewski, J., Myhand, R.C., Schneider, E., Hakim, F., Gress, R., Goldspiel, B., Noone, M.H., Brewster, L.R., Gossard, M.R. and Cowan, K.H. (1997) "A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies", Clinical Cancer Research 3, 755 - 760
  • Brown, G.A., McPherson, J.P., Gu, L., Hedley, D.W., Toso, R., Deuchars, K.L., Freedman, M.H. and Goldenberg, G.J. (1995) "Relationship of DNA topoisomerase IIα and β expression in cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines", Cancer Research 55, 78 - 82
  • Crump, M., Lipton, J., Hedley, D., Sutton, D., Shepherd, F., Minden, M., Stewart, K., Beare, S. and Eisenhauer, E. (1999) "Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study", Leukemia 13 (3), 343 - 347
  • Kancherla, R.R., Nair, J.S., Ahmed, T., Durrani, H., Seiter, K., Mannancheril, A. and Tse-Dinh, Y.-C. (2001) "Evaluation of topotecan etoposide for non-Hodgkin's lymphoma", Cancer 91 (3), 463 - 471
  • Blay, J.-Y., Gomez, F., Sebban, C., Bachelot, R., Biron, P., Guglielmi, C., Hagenbeek, A., Somers, R., Chauvin, F. and Philip, T. (1998) "The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma group", Blood 92, 3562 - 3568

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.